Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond
Open Access
- 30 March 2023
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 61 (3) , 2202202
Abstract
Tezepelumab, a biologic therapy for severe asthma, blocks TSLP activity, subsequently downregulating multiple type 2 inflammatory pathways and reducing airway hyperresponsiveness via eosinophil-independent effects https://bit.ly/3XGpaV3Keywords
Funding Information
- Amgen
- AstraZeneca
This publication has 10 references indexed in Scilit:
- Tezepelumab Reduces Inflammatory Biomarkers as Early as Week 2 and Maintains Reductions Until Week 52 in the Phase 3 NAVIGATOR Severe Asthma TrialJournal of Allergy and Clinical Immunology, 2022
- Is tezepelumab more than just an anti-eosinophil drug?European Respiratory Journal, 2021
- Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet Respiratory Medicine, 2021
- Late Breaking Abstract - Effects of tezepelumab on host epithelial tolerance to virus in patients with uncontrolled asthmaEuropean Respiratory Journal, 2021
- The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)European Respiratory Journal, 2021
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled AsthmaNew England Journal of Medicine, 2021
- Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective studyAnnals of Translational Medicine, 2020
- Tezepelumab in Adults with Uncontrolled AsthmaNew England Journal of Medicine, 2017
- Dupilumab Suppresses Fractional Exhaled Nitric Oxide (FeNO) and Biomarkers of Type 2 Inflammation in Adult Patients with Persistent Uncontrolled Asthma Despite Use of Medium-to-High Dose Inhaled Corticosteroids Plus Long-Acting Beta-Agonists (ICS/LABAs)Journal of Allergy and Clinical Immunology, 2016
- Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic ResponsesNew England Journal of Medicine, 2014